Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin

Future Medicinal Chemistry

Volumn 8, Issue 2, 2016, Pages 117-132

  Fuchs, Beth Burgwyn ^a   Rajamuthiah, Rajmohan ^a   Souza, Ana Carolina Remondi ^b   Eatemadpour, Soraya ^a   Rossoni, Rodnei Dennis ^c   Santos, Daniel Assis ^d   Junqueira, Juliana C ^c   Rice, Louis B ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

antimicrobial; auranofin; Bucillus subtilis; Candida albicans; Cryptococcus neoformans; Enterococcus faecalis; Enterococcus faecium; Staphylococcus aureus

Indexed keywords

AURANOFIN; ANTIINFECTIVE AGENT; THIOREDOXIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM COLONY; CAENORHABDITIS ELEGANS; CANDIDA; CANDIDA GLABRATA; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FUNGICIDAL ACTIVITY; INHIBITORY CONCENTRATION; KLEBSIELLA PNEUMONIAE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM FUNGICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIUM; CHEMISTRY; DRUG EFFECTS; ENTEROCOCCUS; FILOBASIDIELLA; FUNGUS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTI-BACTERIAL AGENTS; AURANOFIN; BACTERIA; CAENORHABDITIS ELEGANS; CRYPTOCOCCUS; ENTEROCOCCUS; FUNGI; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; THIOREDOXINS;

EID: 84958050404     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.182     Document Type: Article

References (41)

1. Cuddy SM. Methicillin-resistant Staphylococcus aureus: a new pandemic? Plast. Surg. Nurs. 28(4), 168-169 (2008).
2. Pfaller M, Messer S, Jones RN, Castanheira M. Antifungal susceptibilities of Candida Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). J. Antibiot. (Tokyo) 68(9), 556-561 (2015).
3. Cleveland AA, Harrison LH, Farley MM et al. Declining Incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE 10, e0120452 (2015).
4. Pan W, Khayhan K, Hagen F et al. Resistance of Asian Cryptococcus neoformans serotype a is confined to few microsatellite genotypes. PLoS ONE 7(3), e32868 (2012).
5. Mdodo R, Moser SA, Jaoko W et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. 54(5), 1-7 (2012).
6. Bii CC, Makimura K, Abe S et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50, 25-30 (2007).
7. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43, 1069-1073 (2006).
8. Rajamuthiah R, Fuchs BB, Jayamani E et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS ONE 9(2), e89189 (2014).
9. Jackson-Rosario S, Cowart D, Myers A et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg. Chem. 14(4), 507-519 (2009).
10. Rhodes MD, Sadler PJ, Scawen MD SS. Effects of Gold(I) antiarthritic drugs and related compounds on Pseudomonas putida. J. Inorg. Chem. 46, 129-142 (1992).
11. Jackson-Rosario S, Self WT. Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J. Bacteriol. 191(12), 4035-4040 (2009).
12. Cell Profiler. www.cellprofiler.org/
13. Clinical and Laboratory Standards Institute. Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically; Approved Standard (8th Edition). M07-A8., CLSI, PA, USA (2009).
14. Clinical and Laboratory Standards Institute. Reference Methods For Broth Dilution Antifungal Susceptibility Testing Of Yeast. CLSI, Wayne, PA, USA (2012).
15. Rajput SB, Karuppayil SM. Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans. SpringerPlus 2(1), 26 (2013).
16. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43(1), 140-143 (2005).
17. Garsin DA, Sifri CD, Mylonakis E et al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl Acad. Sci. USA 98(19), 10892-10897 (2001).
18. Conery AL, Larkins-Ford J, Ausubel FM, Kirienko NV. High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model. Curr. Protoc. Chem. Biol. 6(1), 25-37 (2014).
19. Holland TL, Arnold C, Fowler VG. Clinical management of Staphylococcus aureus bacteremia. JAMA 312(13), 1330-1341 (2014).
20. Kean WF, Hart L, Buchanan WW. Auranofin. Br. J. Rheumatol. 36(5), 560-572 (1997).
21. Cassetta MI, Marzo T, Fallani S, Novelli A, Messori L. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27(4), 787-791 (2014).
22. Rice LB, Carias LL, Rudin S, Wood A, Hutton-Thomas R, Laktic V. Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob. Agents Chemother. 49(12), 5007-5012 (2005).
23. Angelucci F, Sayed AA, Williams DL et al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284(42), 28977-28985 (2009).
24. Tejman-Yarden N, Miyamoto Y, Leitsch D et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob. Agents Chemother. 57(5), 2029-2035 (2013).
25. Bonilla M, Denicola A, Novoselov S V et al. Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J. Biol. Chem. 283(26), 17898-17907 (2008).
26. Lu J, Holmgren A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 66, 75-87 (2014).
27. Missall TA, Lodge JK. Thioredoxin reductase is essential for viability in the fungal pathogen Cryptococcus neoformans. Eukaryot. Cell. 4(2), 487-489 (2005).
28. Ianiri G, Indrum AL. Essential gene discovery in the Basidiomycete Cryptococcus. MBio 6(12), e02334-e02314 (2015).
29. Harbut MB, Vilchèze C, Luo X et al. Auranofin exerts broadspectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA 112(14), 4453-4458 (2015).
30. Debnath A, Parsonage D, Andrade RM et al. A highthroughput drug screen for Entamoeba histolytica identifies a new lead and target. Nature 18(6), 956-960 (2012).
31. Lu J, Vlamis-Gardikas A, Kandasamy K et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394-1403 (2013).
32. Newton GL, Arnold K, Price MS et al. Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. J. Bacteriol. 178(7), 1990-1995 (1996).
33. Holmgren A. Reduction of risulfides by thioredoxin. J. Biol. Chem. 254(18), 9113-9119 (1979).
34. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y. Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J. Bacteriol. 186(2), 326-334 (2004).
35. Stylianou M, Kulesskiy E, Lopes JP, Granlund M, Wennerberg K, Urban CF. Antifungal application of nonantifungal drugs. Antimicrob. Agents Chemother. 58(2), 1055-1062 (2014).
36. Denning DW. Echinocandin antifungal drugs. Lancet 362(9390), 1142-1151 (2003).
37. Dismukes WE. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2), S507-S512 (1993).
38. Enjalbert B. Stress-induced gene expression in Candida albicans: absence of a general stress response. Mol. Biol. Cell 14(4), 1460-1467 (2002).
39. Cuellar-Cruz M, Lopez-Romero E, Ruiz-Baca E, Zazueta-Sandoval R. Differential response of Candida albicans and Candida glabrata to oxidative and nitrosative stresses. Curr. Microbiol. 69(5), 733-739 (2014).
40. Siles SA., Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob. Agents Chemother. 57(8), 3681-3687 (2013).
41. Ozdemir I, Temelli N, Günal S, Demir S. Gold(I) complexes of N-heterocyclic carbene ligands containing benzimidazole: synthesis and antimicrobial activity. Molecules 15(4), 2203-2210 (2010).